Literature DB >> 23107664

[Intestinal parasites in children in Biankouma, Ivory Coast (mountaineous western region): efficacy and safety of praziquantel and albendazole].

K D Adoubryn1, C G Kouadio-Yapo, J Ouhon, N A D Aka, F Bintto, A Assoumou.   

Abstract

Schistosomiasis and soil-transmitted helminthiasis are a global public health problem, especially among schoolchildren. The purpose of this study was to determine the overall and specific prevalences of intestinal helminth infection and to assess the clinical efficacy, tolerance, and safety of praziquantel and albendazole for treating it. A descriptive cross-sectional study based on random sampling with one degree of freedom was conducted from November 2006 to March 2007 in the primary schools of Biankouma, Côte d'Ivoire. Stool samples were collected from 386 children aged from 4 to 15 years and analyzed by direct examination, with both the simplified Ritchie and Kato techniques. Children infected by schistosomiasis and soil-transmitted helminthiasis eggs were treated with praziquantel (40 mg/kg in a single dose), albendazole (400 mg/kg in a single dose) or both, as deemed necessary. The prevalence rate of intestinal parasite infection was 55.2%, including overall 15.4% with more than one parasite: two in 14.2% and three in 1.2%. Infection was correlated with male gender and older age. The most frequent helminths were Schistosoma mansoni (35.5%) and Necator americanus (25.9%). The efficacy rate for praziquantel, defined as parasite-free stools, was 57.7% on day 14 and 80.9% on day 90. The efficacy rate for albendazole on day 7 was 96.1% for Ascaris lumbricoides, 93% for Necator americanus and 81.3% for Trichuris trichiura. Adverse effects were common (40.8%) but minor (abdominal pain, headache, and itching) within 2 to 4 hours after intake of praziquantel.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23107664     DOI: 10.1684/mst.2012.0048

Source DB:  PubMed          Journal:  Med Sante Trop        ISSN: 2261-3684


  5 in total

1.  Randomized, controlled, assessor-blind clinical trial to assess the efficacy of single- versus repeated-dose albendazole to treat ascaris lumbricoides, trichuris trichiura, and hookworm infection.

Authors:  Ayola A Adegnika; Jeannot F Zinsou; Saadou Issifou; Ulysse Ateba-Ngoa; Roland F Kassa; Eliane N Feugap; Yabo J Honkpehedji; Jean-Claude Dejon Agobe; Hilaire M Kenguele; Marguerite Massinga-Loembe; Selidji T Agnandji; Benjamin Mordmüller; Michael Ramharter; Maria Yazdanbakhsh; Peter G Kremsner; Bertrand Lell
Journal:  Antimicrob Agents Chemother       Date:  2014-02-18       Impact factor: 5.191

2.  Schistosomiasis and soil-transmitted helminthiasis preventive chemotherapy: Adverse events in children from 2 to 15 years in Bengo province, Angola.

Authors:  Manuel Lemos; Joao M Pedro; Cláudia Fançony; Sofia Moura; Miguel Brito; Susana Vaz Nery; Carlos Pinto Sousa; Henrique Barros
Journal:  PLoS One       Date:  2020-03-11       Impact factor: 3.240

3.  Risk factors for intestinal parasite portage in an informal suburb on the West coast of Madagascar.

Authors:  Zara Nomentsoa Razafiarimanga; Yves Boris Kouakou Yao; Minoarison Rajerison; Lovarintsoa Judicael Randriamampianina; Soanandrasana Rahelinirina; Radolalaina Rakotoarison; Bastaraud Alexandra; Hariniaina Elisoa; Handshumacher Pascal; Jambou Ronan
Journal:  Parasite Epidemiol Control       Date:  2022-08-19

4.  A school-based cross-sectional survey of adverse events following co-administration of albendazole and praziquantel for preventive chemotherapy against urogenital schistosomiasis and soil-transmitted helminthiasis in Kwale County, Kenya.

Authors:  Sammy M Njenga; Paul M Ng'ang'a; Mariam T Mwanje; Fatuma S Bendera; Moses J Bockarie
Journal:  PLoS One       Date:  2014-02-10       Impact factor: 3.240

5.  Molecular prevalence of intestinal parasites infections in children with diarrhea in Franceville, Southeast of Gabon.

Authors:  Sandrine Lydie Oyegue-Liabagui; Nal Kennedy Ndjangangoye; Lady Charlene Kouna; Gwladys Mirlande Lekolo; Franck Mounioko; Sylvie Kwedi Nolna; Jean Bernard Lekana-Douki
Journal:  BMC Infect Dis       Date:  2020-05-15       Impact factor: 3.090

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.